Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Metformin, Sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP1 receptor agonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4,888 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Conditions
Advanced Renal Cell Carcinoma, Advanced Melanoma
Interventions
Sitagliptin, Pembrolizumab
Drug
Lead sponsor
Fernando Maciel Barbosa
Other
Eligibility
18 Years to 99 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Diabetes Mellitus
Interventions
Saxagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Anti-Diabetic Medications to Fight PD and LBD

NCT06263673
Conditions
Lewy Body Dementia, Parkinson Disease
Interventions
Sitagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Coronavirus Infection, Type 2 Diabetes
Interventions
Linagliptin, Insulin regimen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
179
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
Conditions
Medullary Thyroid Carcinoma
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
93,600,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Parsippany, New Jersey
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of DPP4 Inhibition on Growth Hormone Secretion

NCT01701973
Conditions
Obesity
Interventions
Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 75 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Fullerton, California • Long Beach, California • Orange, California + 24 more
Conditions
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Interventions
Sitagliptin
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Diabetes
Interventions
Empagliflozin, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
103,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

ADA Linagliptin in Long Term Care

NCT02061969
Conditions
Diabetes
Interventions
linagliptin, insulin glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Conditions
Type 2 Diabetes
Interventions
Sitagliptin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

DPP-4 Inhibition and TZD for DM Prevention

NCT01006018
Conditions
Prediabetic State
Interventions
Sitagliptin + Pioglitazone PLACEBO, Sitagliptin + Pioglitazone, PLACEBO
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more